Product Description
NXtec™ D007-B1 Acute Lymphoblastic Leukemia

To be used with the digitalMLPA NXtec Protocol.

Version B1
Check the version of your product on the probemix label to ensure you are reading the appropriate product description. As compared to version A1, one probe has been removed, 16 probes have been replaced, and 194 new probes targeting additional regions and genes of (emerging) interest have been added. Additions include new probes for copy number detection of *DNMT3A*, *MEF2C*, *CDKN1B*, *KRAS*, *EPOR*, 6q15-q16.1 deletion region (incl *CASP8AP2*, *BACH2* and other genes), 13q12 microdeletion region (*CDX2, FLT3, PAN3, FLT1*), 17q21 deletion region (*UBTF, ATXN7L3*), 20q11.21 (dic(9;20) breakpoint, incl. *DNMT3B*) and 22q11.22 microdeletion region (up and downstream of *VPREB1*). New probes are also included for *MEF2D* fusion indication including partners *BCL9*, *HNRNPH1*, *HNRNPUL1*, and *DAZAP1,* and for *TCF3* fusion indication including partners *PBX1* and *HLF*. Details about the added and changed probes can be found in the probemix specific Probe Information File (PIF). For complete product history see page 25.

Catalogue numbers
- **D007-025R:**   NXtec D007 Acute Lymphoblastic Leukemia, 25 reactions
- **D007-050R:**   NXtec D007 Acute Lymphoblastic Leukemia, 50 reactions
- **D007-100R:**   NXtec D007 Acute Lymphoblastic Leukemia, 100 reactions

NXtec D007-B1 Acute Lymphoblastic Leukemia (hereafter: D007 Acute Lymphoblastic Leukemia) is to be used in combination with:

1. NXtec Reagent Kit (Cat No: DRK01-IL, DRK05-IL, DRK20-IL)
2. Barcode plates:
    NXtec Barcode Plate 1 (Cat No: BP01-IL (from lot 03-009-xxxxxx and higher))
    NXtec Barcode Plate 2 (Cat No: BP02-IL (from lot 03-008-xxxxxx and higher))

    N.B. The three-digit number between dashes (e.g. -008-) will increase with every new barcode plate lot.

3. Data analysis software version Coffalyser digitalMLPA™ 2.5.0 or higher (Cat No: n.a.)

Volumes and ingredients

Volumes			Ingredients
D007-025R	**D007-050R**	**D007-100R**	
40 µl	80 µl	160 µl	Synthetic oligonucleotides, Tris-HCl, EDTA, DTT

The probemix is not known to contain any harmful agents. Based on the concentrations present, none of the ingredients are hazardous as defined by the Hazard Communication Standard. A Safety Data Sheet (SDS) is not required for this product: none of the ingredients contain dangerous substances at concentrations requiring distribution of an SDS (as per Regulation (EC) No 1272/2008 [EU-GHS/CLP] and 1907/2006 [REACH] and amendments).

Storage and handling

Recommended storage conditions		
	-15°C / -25°C	☀

A shelf life of until the expiry date is guaranteed, when stored in the original packaging under recommended conditions. For the exact expiry date, see the label on the vial. This product should not be exposed to more than 25 freeze-thaw cycles. Do not use the product if the packaging is damaged or opened. Leave chemicals in original containers. Waste material must be disposed of in accordance with the national and local regulations.

Certificate of Analysis
Information regarding quality tests is available at www.mrcholland.com.

Precautions and warnings
For professional use only. Always consult the most recent product description AND the digitalMLPA NXtec Protocol before use: www.mrcholland.com. It is the responsibility of the user to be aware of the latest scientific knowledge of the application before drawing any conclusions from findings generated with this product.

> **Two Coffalyser digitalMLPA product sheets are available for data analysis, a *default* product sheet and a *near haploid_low hypodiploid* product sheet. Different reference probe selections ensure correct data normalisation in samples with gross chromosomal aberrations. <u>Prior knowledge of the ploidy status</u> based on DNA indexing and/or karyotyping is necessary for proper analysis of (low) hypodiploid, near haploid and hyperdiploid samples using digitalMLPA data obtained with D007 Acute Lymphoblastic Leukemia.**

General information
NXtec D007-B1 Acute Lymphoblastic Leukemia is a **research use only (RUO)** assay for the detection of deletions or gains in 73 genes and eight chromosomal regions, as specified in Table 2, which are associated with acute lymphoblastic leukemia (ALL).

ALL is the most common childhood cancer comprising multiple genetically heterogeneous subtypes of malignant clonal expansions of immature T- or B-cells. Although current treatment regimens have resulted in 5-year event-free survival rates of >90% in children, disease relapse is associated with a poor outcome (Roberts and Mullighan 2015). The genetic alterations in different subtypes of ALL are well characterised and include gross chromosomal aberrations such as hyper-/hypodiploidy, but also fusion genes, gene deletions, gains and amplifications. D007 Acute Lymphoblastic Leukemia is designed to detect these key genetic copy number alterations in childhood ALL.

This probemix is not CE/FDA registered for use in diagnostic procedures. The digitalMLPA technique is covered by US patent 6,955,901 and corresponding patents outside the US and digitalMLPA products are sold under a license of InVitae corporation on patent US 9,624,533. The purchase of this product includes a license on these patents to use only this amount of product solely for the purchaser's own use.

Probemix content
A total number of 951 probes is included in D007-B1 Acute Lymphoblastic Leukemia, this consists of:
- 524 target probes detecting copy number alterations involved in ALL. See the Probe Information File and Table 2 for more details.
- 250 karyotyping probes, covering all existing chromosome arms (at the middle, near the centromeres and near the telomeres). See Table 2 for all chromosomal regions and genes included. A set of these karyotyping probes are used as reference probes, as indicated in Table 3 and 4.
- More than 160 control probes and fragments: these include probes for sample identification and probes for detection of errors or deviations when performing digitalMLPA assays, impurities in and fragmentation of the DNA samples, ligase and polymerase activity and extent of hybridisation.

The total number of probes can be used to calculate the number of reactions that can be combined into one sequencer run. See chapter "Amplicon Quantification by Illumina Sequencers" in the digitalMLPA NXtec Protocol or the calculator tool available at support.mrcholland.com.

Reference probes
The 95 selected reference probes as defined in the *D007-B1 default product sheet* are a subset of karyotyping probes in regions that show minimal copy number changes in ALL, as indicated in Table 2. This was determined using information from the Progenetix oncogenomic online resource, Database of Genomic Variants (DGV), Broad Institute TCGA Copy Number Portal, and Catalogue of Somatic Mutations in Cancer (COSMIC) Cancer Gene Census. This selection is applicable for most ALL subtypes with (small) CNAs, chromosomal (arm) gains and losses, and for samples with (high) hyperdiploidy.

As the number of chromosomes with a normal diploid copy number retained in samples with low hypodiploidy and near haploidy is limited, a different selection of reference probes is required for optimal data normalisation of these sample types. Based on several publications (Harrison et al. 2004, Nachman et al. 2007, Holmfeldt et al. 2013, Safavi et al. 2017, Caroll et al. 2019), 84 suitable reference probes were selected on the chromosomes retained in both low hypodiploidy and near haploidy (chromosomes 8, 10, 14, 18, 21 and X / Y). In addition, a small number of reference probes was added for additional chromosomes reported to be retained in low hypodiploidy (chromosomes 1, 5, 6, 11 and 22). The number of selected reference probes per chromosome in this product sheet is indicated in Table 4. More information on the use of the *D007-B1 near haploid_low hypodiploid product sheet* can be found in section "Data analysis" below.

Gene structure and transcript variants
Entrez Gene shows transcript variants of each gene: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene
For NM_ mRNA reference sequences: http://www.ncbi.nlm.nih.gov/sites/entrez?db=nucleotide
Matched Annotation from NCBI and EMBL-EBI (MANE): http://www.ncbi.nlm.nih.gov/refseq/MANE/
Tark – Transcript Archive: http://tark.ensembl.org/

digitalMLPA technique
digitalMLPA™ (Benard-Slagter et al. 2017) combines the robustness and simplicity of the trusted SALSA® MLPA® technology (Schouten et al. 2002) with next-generation sequencing. For NXtec products a specific protocol of the digitalMLPA technique is used. The principles of digitalMLPA and the protocol for the NXtec products are described in the digitalMLPA NXtec Protocol (www.mrcholland.com). More information on the use of MLPA in tumour applications can be found in Hömig-Hölzel and Savola (2012).

digitalMLPA technique validation
Internal validation using 16 different DNA samples from healthy individuals is required, in particular when using this NXtec probemix for the first time, or when pre-analytical steps, DNA extraction method or the instruments used are changed. This validation experiment should result in a standard deviation ≤0.10 for all reference probes.

Required specimens
Extracted DNA from peripheral blood and/or bone marrow, free from impurities known to affect digitalMLPA reactions. MRC Holland has tested and can recommend the following extraction methods:
- QIAGEN Autopure LS (automated) and QIAamp DNA mini/midi/maxi kit (manual)
- Promega Wizard Genomic DNA Purification Kit (manual)
- Salting out (manual)

For more information see the digitalMLPA NXtec Protocol, section DNA sample treatment. The minimum percentage of tumour cells required for reliable analysis is 30% (Al Zaabi et al. 2010, Coll-Mulet et al. 2008, Benard-Slagter et al. 2017). We would advise to use tumour samples with at least 50% tumour cell content to minimize the variation in tumour cell estimation, and to allow robust data-analysis and detection of potential subclonal aberrations. We therefore recommend to evaluate the tumour samples by a pathologist, and in case of low tumour cell percentage, to make use of enrichment methods, prior DNA extraction.

Reference samples
A sufficient number (≥3) of different reference samples from healthy individuals should be included in each digitalMLPA experiment for data normalisation. As X- and Y-chromosome specific probes are included in this probemix, at least three male reference samples need to be used per experiment. Please note that this applies **only** when software version Coffalyser digitalMLPA 2.5.0 or higher is used. In case an earlier version is used a different reference sample selection is needed, which includes at least three male AND three female reference samples. Pooled DNA from different sexes can never be used as reference samples for D007 Acute Lymphoblastic Leukemia analysis.

All samples tested, including reference DNA samples, should be derived from the same tissue type, handled using the same procedure, and prepared using the same DNA extraction method when possible. More

information regarding the selection and use of reference samples can be found in the digitalMLPA NXtec Protocol.

Positive control DNA samples
MRC Holland cannot provide positive DNA samples. Inclusion of a positive sample in each experiment is recommended. Coriell Institute (https://catalog.coriell.org) and Leibniz Institute DSMZ (https://www.dsmz.de/home.html) have a diverse collection of biological resources which may be used as a positive control DNA sample in your digitalMLPA experiments. The quality of cell lines can change, therefore deviations to the indicated copy number alteration (CNA) findings might occur. A list of positive control samples that have been tested with D007-B1 Acute Lymphoblastic Leukemia at MRC Holland can be found on the product page: https://www.mrcholland.com/product/D007.

Data analysis
Coffalyser digitalMLPA 2.5.0 or higher must be used for data analysis in combination with the appropriate lot-specific product sheet. Coffalyser digitalMLPA is freely downloadable at www.mrcholland.com. Use of other non-proprietary software may lead to inconclusive or false results. Normalisation of results should be performed within one experiment. The Coffalyser digitalMLPA User Manual contains technical guidelines and information on data evaluation/normalisation.

Separate product sheet for near haploid or low hypodiploid samples
As long as more than 50% of the sequences targeted by the reference probes have a normal copy number (CN=2) in the test sample, the correct baseline will be detected and data will be correctly normalised using the Coffalyser digitalMLPA default product sheet. The reference probe selection in the D007-B1 default product sheet is also suitable for use on high hyperdiploid samples, as >50% of the reference probes are expected to have a normal diploid copy number in high hyperdiploid samples. However, for ALL samples that would be classified as near haploid or low hypodiploid samples by conventional karyotyping or DNA indexing, loss of the majority of chromosomes would result in wrong baseline detection using the *default* reference probe selection. A separate product sheet is available that should be used for correct baseline detection and ratio determination in these low hypodiploid or near haploid ALL samples. The reference probe selection in this D007-B1 *near haploid_low hypodiploid* product sheet is based on chromosomes frequently retained in these near haploid or low hypodiploid sample types (see Table 4).

Please note that prior knowledge of the ploidy status based on DNA indexing and/or karyotyping is necessary for proper analysis of (low) hypodiploid, near haploid and hyperdiploid samples using digitalMLPA data obtained with D007 Acute Lymphoblastic Leukemia.

Use of the wrong product sheet for analysis with Coffalyser digitalMLPA will result in incorrect baseline detection and therefore incorrect normalization for all probes in the probemix. For example, a near haploid sample wrongfully analysed with the *D007-B1 default* product sheet could be interpreted as a sample with gains of a few chromosomes and or genes/regions.

Interpretation of results
The expected results for (pseudo)autosomal probes are allele copy numbers of 2 (normal), 1 or 0 (deletion), $\geq$ 3 (gain). The same results can be expected for the X-chromosome-specific probes in female samples. For the X-chromosome-specific probes in male samples, expected copy numbers are 1 (normal), 0 (deletion) or 2 (gain).

The standard deviation of all probes in the reference samples should be ≤0.10. When this criterion is fulfilled, the following cut-off values for the inter ratio of the probes can be used to interpret digitalMLPA results.

Copy number status	Inter ratio	
	(pseudo)autosomal probes / X-chromosome-specific probes in female samples	X- and Y-chromosome-specific probes in male samples
Normal	0.85 < ratio < 1.15	0.80 < ratio < 1.20
Deletion *	ratio < 0.75	ratio < 0.70
Gain ±	ratio > 1.25	ratio > 1.30
Ambiguous copy number	All other values	All other values

* Ratios might indicate a (subclonal) biallelic deletion when autosomal inter ratios are ≤0.30.
± Ratios might indicate an amplification when inter ratios are ≥2.15.

Please note that these above mentioned inter ratios are affected both by percentage of tumour cells and by possible subclonality. In case of a deletion that is subclonal and/or a lower percentage of tumour cells, the inter ratio may be higher than expected. For example, a monoallelic deletion in a sample with 50% tumour cell content or a monoallelic deletion present in 50% of the tumour cells, will result in an inter ratio around 0.75. However, the same (ambiguous) inter ratio of 0.75 will also be found in a sample with a biallelic deletion and a tumour cell percentage of 25%, or a subclone harbouring a biallelic deletion comprising 25% of all tumour cells. The digitalMLPA technique cannot discriminate between these two scenarios.

More information on this can be found on our website.

General notes on digitalMLPA interpretation:

- Arranging probes according to chromosomal location facilitates interpretation of the results. Analysis of parental samples may be necessary for correct interpretation of complex results.
- False positive results: Please note that abnormalities detected by a single probe (or multiple consecutive probes) still have a chance of being a false positive result. Incomplete DNA denaturation (e.g. due to salt contamination) can lead to a decreased probe read count of several consecutive probes, in particular for probes located in or near a GC-rich region. The use of an alternative DNA extraction method or an additional purification step (e.g. with ethanol precipitation or silica column based kits) may resolve such cases. Control probes are present in all digitalMLPA probemixes that provide a warning for incomplete DNA denaturation. Sequence changes (e.g. single nucleotide variants (SNVs), point mutations) in the target sequence detected by a probe can also lead to false-positive results.
- False positive results (gains): Contamination of DNA samples with cDNA or PCR amplicons of individual exons can lead to an increased probe read count (Varga et al. 2012). Analysis of an independently collected secondary DNA sample can exclude these kinds of contamination artefacts.
- Normal copy number variation in healthy individuals is described in the database of genomic variants: http://dgv.tcag.ca/dgv/app/home. Users should always consult the latest update of the database and scientific literature when interpreting their findings.
- Not all abnormalities detected by digitalMLPA are pathogenic. For many genes, more than one transcript variant exists. Copy number changes of exons that are not present in all transcript variants may not have clinical significance. In some genes, intragenic deletions are known that result in very mild, or no disease (Schwartz et al. 2007). Gains that include the first or last exon of a gene (e.g. exons 1-3) might in some cases not result in inactivation of that gene copy.
- Copy number changes detected by reference or flanking probes are unlikely to have any relation to the condition tested for.

D007-B1 Acute Lymphoblastic Leukemia specific notes
- In samples from tumour tissues, reference probes are more prone to have deviating copy number results as compared to blood-derived germline samples, which could result in warnings in Coffalyser digitalMLPA output about reference probe quality.
- The SNP-specific control probes included in D007 Acute Lymphoblastic Leukemia can be used for sample identification. However, they will not indicate contamination of sample DNA.

- The IGHM and IGLV locus undergo recombination during B cell maturation. Hence, final ratios of probes targeting these two loci may be affected by the population of B cell clones present in a sample, which can change with age, disease, or clonal expansion during infection.

Limitations of the procedure
- DNA indexing or karyotyping should be done to determine the ploidy of the sample. digitalMLPA cannot distinguish haploid or complete triploid or tetraploid samples (with a loss or gain of all chromosomes) as compared to diploid samples, as the Coffalyser software determines a baseline based on the reference probes in each individual sample. In addition, to select the correct Coffalyser product sheet to properly analyse hyperdiploid (*default* product sheet) and near-haploid or low-hypodiploid samples (*near haploid_low hypodiploid* product sheet), pre-existing knowledge is needed regarding the ploidy status.
- Other techniques (e.g. karyotyping and FISH) are more suitable to detect cases with masked hypodiploidy.
- The majority of the defects in the genes included in this D007 Acute Lymphoblastic Leukemia Probemix are deletions, gains or amplifications, but point mutations can occur which will not be detected by this probemix.
- digitalMLPA cannot detect any changes that lie outside the target sequence of the probes and will not detect most copy number neutral inversions or translocations. Even when digitalMLPA did not detect any aberrations, the possibility remains that biological changes in that gene or chromosomal region *do* exist but remain undetected.
- **Warning:** Small changes (e.g. SNVs, small indels) in the sequence targeted by a probe can cause false positive results. Sequence changes can reduce the probe read count by preventing ligation of the probe oligonucleotides or by destabilising the binding of a probe oligonucleotide to the sample DNA. Deviations detected by this product should be confirmed, and single-probe deviations always require confirmation. Sequencing of the target region is recommended. Please contact MRC Holland for more information: info@mrcholland.com.
- digitalMLPA analysis on tumour samples provides information on the average situation in the cells from which the DNA sample was purified. In addition, subclonality of the aberration affects the inter ratio of the corresponding probe. Furthermore, there is always a possibility that reference probes *do* show a copy number alteration especially in samples with complex karyotypes or ploidy changes potentially complicating data normalisation (as digitalMLPA is a relative technique). In such cases knowledge from DNA indexing or karyotyping can support accurate interpretation of probe inter ratios.

Confirmation of results
Copy number changes of multiple consecutive probes detected with D007-B1 Acute Lymphoblastic Leukemia should be verified by another method when possible. MLPA probemixes are available for many genes and chromosomal regions in D007-B1 Acute Lymphoblastic Leukemia. The MLPA probemixes mentioned in section 'Related SALSA® MLPA® probemixes' in this product description contain probes with a different ligation site that can be used for initial confirmation of results. Alternatively, copy number changes can be confirmed by another independent technique such as long range PCR, qPCR, array CGH, FISH or Southern blotting.

Copy number changes detected by only a single probe always require confirmation by another method. An apparent deletion detected by a single probe can be due to e.g. a mutation/polymorphism that prevents ligation or destabilises the binding of probe oligonucleotides to the DNA sample. Sequence analysis can establish whether mutations or polymorphisms are present in the probe target sequence. The finding of a heterozygous mutation or polymorphism indicates that two different alleles of the sequence are present in the sample DNA and that a false positive result was obtained.

COSMIC mutation database
http://cancer.sanger.ac.uk/cosmic. We strongly encourage users to deposit positive results in the COSMIC mutation database. Recommendations for the nomenclature to describe deletions/gains of one or more exons can be found on http://varnomen.hgvs.org/.

Please report false positive results due to SNVs and unusual results to MRC Holland: info@mrcholland.com.

Table 1. D007-B1 Acute Lymphoblastic Leukemia probe targets

Chromosomal position (hg38)	Gene	NM sequence [a]	# probes / # exons in gene	Remarks and literature
1p33	*TAL1*	NM_001290403.2	4/5	*STIL-TAL1* fusion [¥] in 10-30% of T-ALL
1p33	*STIL*	NM_001048166.1	4/17	Cavé et al. 2004, Patra et al. 2021
1q21.2	*BCL9* [¥]	NM_004326.4	6/10	*MEF2D-BCL9* fusion[¥] in 7% in B-ALL Gu et al. 2016, Ohki et al. 2019, Suzuki et al. 2016
	*GJA5**	-	1/2	*Included as flanking probe for BCL9*
1q22	*MEF2D** [¥]	NM_005920.4	9/12	*MEF2D* rearrangements [¥]in up to 7% of B-ALL Gu et al. 2016, Yuki et al. 2004
1q23.3	*PBX1** [¥]	NM_002585.4	9/9	*TCF3-PBX1* fusion [¥] in 6% of B-ALL Barbosa et al. 2018, Paulsson et al. 2007 Rowsey et al. 2019
2p23.3	*DNMT3A**	NM_022552.5	5/23	*DNMT3A* deletions in 1% of T-ALL Bond et al. 2019
2q34	*IKZF2*	NM_001387220.1	3/9	Deletions of *IKZF2* in 50% of low-diploid ALL Holmfeldt et al. 2013
3p14.2	*FHIT* «	NM_002012.4	3/10	Deletions of *FHIT* in 4% childhood and 7% adult ALL Okamoto et al. 2010
3q13.2	*CD200* «	NM_005944.7	3/6	*CD200/BTLA* deletions in 5% B-ALL
3q13.2	*BTLA*	NM_181780.4	3/5	Ghazavi et al. 2015
3q26.32	*TBL1XR1*	NM_024665.7	4/16	Deletions in 15% of *ETV6-RUNX1* positive ALL; associated with glucocorticoid therapy resistance Parker et al. 2008, Jones et al. 2014
	LINC00501	NR_047465.1	2/2	*Included as flanking probes for TBL1XR1*
4q25	*LEF1*	NM_016269.5	5/12	*LEF1* deletions in 11% of T-ALL Gutierrez et al. 2010
4q31.23	*NR3C2*	NM_000901.5	3/9	Deletions of *NR3C1* and *NR3C2* are associated with relapsed ALL Safavi et al. 2014, Kuster et al. 2011
5q14.3	*RASA1**	-	1/25	*Included as flanking probe for MEF2C*
	*MEF2C**	NM_002397.5	5/11	*MEF2C* deletions in 10% of T-ALL Homminga et al. 2011
5q extent of deletion - 5q31.2	*EGR1, CTNNA1*	-	1 probe for each gene	Recurrent 5q (terminal) deletions T-ALL (5q31.2-q35.3) La Starza et al. 2016
5q31.3	*NR3C1* «	NM_000176.3	5/9	Deletions of *NR3C1* and *NR3C2* are associated with relapsed ALL Safavi et al. 2014, Kuster et al. 2011
5q32	*PDGFRB*[¥]	NM_002609.4	4/23	*EBF1-PDGFRB* fusion [¥] in B-cell precursor ALL, sensitive to tyrosine kinase inhibitors Lengline et al. 2013, Weston et al. 2013
5q33.1	*RPS14, SPARC*	-	1 probe for each gene	Recurrent 5q (terminal) deletions T-ALL (5q31.2-q35.3) La Starza et al. 2016
5q33.3	*EBF1*[¥]	NM_024007.5	5/16	*EBF1* deletions in 25% of relapsed ALL Yang et al. 2008
5q35.3	*HNRNPH1** [¥]	NM_001257293.2	4/14	*MEF2D* fusion [¥] partner in B-ALL Ohki et al. 2019
5q extent of deletion – 5q35.3	*SQSTM1, FLT4*	-	1 probe for each gene	Recurrent 5q (terminal) deletions T-ALL (5q31.2-q35.3) La Starza et al. 2016
6q extent of deletion - 6q14.3	*HTR1E**	-	1 probe for each gene	6q15-q16.1 deletions in 10% of T-ALL Cordas et al. 2018
6q15	*SLC35A1*, ORC3**			
6q15	*CASP8AP2* «	NM_001137667.2	5/11	*CASP8AP2* deletions in 12% of T-ALL Remke et al. 2009
6q15	*BACH2**	NM_021813.4	3/9	6q15-q16.1 deletions in 10% of T-ALL

Chromosomal position (hg38)	Gene	NM sequence [a]	# probes / # exons in gene	Remarks and literature
6q15	*MAP3K7**	NM_145331.3	5/17	Cordas et al. 2018
6q15	*CASC6**		1/4	
6q16.1	*EPHA7**	NM_004440.4	5/17	
6q extent of deletion - 6q16.1	*MANEA**, *KLHL32**, *MMS22L**, *POU3F2**	-	1 probe for each gene	
6q23.3	*MYB*	NM_001130173.2	3/16	**Gain in 8-15% of T-ALL** Clappier et al. 2007, O'Neil et al. 2007
7p12.2	*IKZF1*	NM_006060.6	15/8	**Poor prognostic factor, alone or in combination with other CNAs** Boer et al. 2016, Mullighan et al. 2008a (note: different exon numbering), Stanulla et al. 2018, Lopes et al. 2023 Specific **intragenic deletions might lead to different clinical outcomes.** Chang et al. 2024
		NM_001291837.2	1 probe in alternative exon 1	
		NM_001291845.2 / NM_001291846.2	2 probes in alternative exon 4	
	IKZF1 regulatory region	NM_006060.6 / NM_001410879.1	7 probes upstream of exon 1	**Deletions of *IKZF1* exon 1 and 5' untranscribed regulatory regions result in haploinsufficiency** Stanulla et al. 2020
7q34-q35	*EPHA1*	NM_005232.5	3/18	***EPHA1* is thought to be an important factor in T-lymphocyte development** Charmsaz et al. 2013
7q36.1	*EZH2*	NM_004456.5	3/20	**Deletions of *EZH2* in T-ALL** Ntziachristos et al. 2012, Zhang et al. 2012
8q12.1	*TOX*	NM_014729.3	3/9	**Recurrent deletions of *TOX* in T-ALL** Mullighan et al. 2009a, Yu et al. 2015
9p24.1	*JAK2*	NM_004972.4	8/25	**Deletions of *JAK2* reported in up to 7% of (high-risk) B-ALL cases** Bhandari et al. 2017, Salmoiraghi et al. 2013, Roberts et al. 2012
9p21.3	*MLLT3*	NM_004529.4	4/11	**Deletions of *MLLT3* in 26% of T-ALL** Mullighan et al. 2007
9p21.3	*MTAP*	NM_002451.4	3/8	**Deletion of *MTAP* in 11% of B-ALL** Mirebeau et al. 2006, Bertin et al. 2003
9p21.3	*CDKN2A*	NM_000077.5 (p16INK4a) NM_058195.4 (P14ARF)	10/3	***CDKN2A* and *CDKN2B* deletions in 35-50% of ALL** Sulong et al. 2009 **Included in *IKZF1*ᵖˡᵘˢ profile – frequently co-deleted in ALL, unfavorable prognosis** Stanulla et al. 2018
		NM_001195132.2 (p16gamma)	2 probes in exon 3 of alternative transcript	
		NM_001363763.2 (isoform 6)	1 probe in alternative exon 1	
9p21.3	*CDKN2B*	NM_004936.4	3/2	
9p13.2	*PAX5* «	NM_016734.3	11/10	**Large deletions of *PAX5*, may include *CDKN2A/2B*. PAX5alt, including Intragenic *PAX5* amplifications is associated with a high incidence of relapse .** Schwab et al. 2013, Schwab et al. 2017, Chang et al. 2024 **Included in *IKZF1*ᵖˡᵘˢ profile – frequently co-deleted in ALL, associated with poor prognosis** Stanulla et al. 2018
	PAX5 flanking	NM_016734.3	1 probe upstream of *PAX5*	**To determine the extent of the *PAX5* deletion.** Mullighan et al. 2007
		NM_032226.3	2 probes in *ZCCHC7* «	
9q34.12	*ABL1* ¥	NM_005157.6	5/11	

Chromosomal position (hg38)	Gene	NM sequence [a]	# probes / # exons in gene	Remarks and literature
9q34.13	NUP214 ¥	NM_005085.4	5/36	**NUP214-ABL1 fusion gene ¥ in 6-8% ALL** Craux et al. 2009, Roberts et al. 2012, Patra et al. 2021
9q34.3	NOTCH1	NM_017617.5	7/34	**Activating intragenic deletions in NOTCH1** Haydu et al. 2012
10q23.31	PTEN	NM_000314.8	20/9	**Deletions of PTEN in 9% of ALL cases; resistance to chemotherapy and early treatment failure** Zuurbier et al. 2012, Mendes et al. 2014
10q25.1-q25.2	ADD3	NM_016824.5	3/15	**Recurrent deletion of ADD3 in B-ALL** Mullighan et al. 2009a, Olsson et al. 2014
11p15.4	LMO1	NM_002315.3	3/4	**Oncogenic transcription factor, LMO1 overexpressed in T-ALL** Oram et al. 2013
11p13	LMO2 ¥	NM_005574.4	4/6	**RAG2-LMO2 fusion ¥ in 4% of pediatric T-ALL** Van Vlierberghe et al. 2006
11p13	CD44	NM_000610.4	1/18	
11p13	SLC1A2	NM_004171.4	1/11	
11p12	RAG2 « ¥	NM_000536.4	2/2	
12p13.2	ETV6	NM_001987.5	8/8	**Rearrangements and fusions (e.g. in ETV6-RUNX1 fusion); microdeletions at breakpoint** Ko et al. 2011
12p13.1	CDKN1B*	NM_004064.5	3/3	**Deletions of CDKN1B in 12% of T-all** Colomer-Lahiguera et al. 2017
12p12.1	KRAS*	NM_004985.5	5/5	**Focal deletions of KRAS in 6% of adult Philadelphia chromosome-positive ALL** Fedullo et al. 2019
12q21.33	BTG1	NM_001731.3	2/2	**BTG1 deletions extend to downstream area; associated with Down syndrome (DS-)ALL** Waanders et al. 2012
		-	3 probes downstream of BTG1	
13q12.2	CDX2*	NM_001265.6	2/3	**13q12.2-q12.3 deletions in up to 2% of B-ALL** Yang et al. 2020
	URAD*	-	1/2	
	FLT3*	NM_004119.3	8/24	
	PAN3*	NM_175854.8	16/19	
	PAN3-AS1*	NR_029383.1	1/2	
13q12.3	FLT1*	NM_002019.4	4/30	
13q14.2	RB1	NM_000321.3	9/27	**Deletions of RB1 in ALL, especially associated with iAMP21** Schwab et al. 2013
	RB1 flanking	-	5' region: 1 probe, ITM2B	
			3' region: 4 probes, RCBTB2, CDADC1, DLEU2, DLEU1	
14q32.33	IGHM	NG_001019.6	2/6	**Non-functional rearrangements/deletions in BCR-ABL-positive B-ALL** Trageser et al. 2009, Chen et al. 2016
15q14	SPRED1	NM_152594.3	3/7	**Recurrent (focal) deletions of SPRED1 in relapse cases** Olsson et al. 2014, Mullighan et al. 2008b
16p13.3	CREBBP	NM_004380.3	3/31	**Deletions of CREBBP in 1-2% of relapsed ALL cases** Mullighan et al. 2011, Vicente et al. 2015
16q22.1	CTCF	NM_006565.4	3/12	**Deletions of CTCF in 2-3% of T-ALL** Vicente et al. 2015
17p13.1	TP53	NM_000546.6	13/11	

Chromosomal position (hg38)	Gene	NM sequence [a]	# probes / # exons in gene	Remarks and literature
			1 probe downstream of TP53	**Single allele deletions of *TP53* or combined with mutated other allele in 2-14% of ALL cases** Agirre et al. 2003
17q11.2	*NF1*	NM_001042492.3	3/58	**Deletions of *NF1* in 11% of T-ALL; poor response to induction therapy** Balgobind et al. 2008
17q11.2	*SUZ12*	NM_015355.4	3/16	**Deletions of *SUZ12* in T-ALL** Zhang et al. 2012, Ntziachristos et al. 2012
17q12	*IKZF3*	NM_012481.5	3/8	**Deletions of *IKZF3* especially in hypodiploid ALL** Mullighan et al. 2007, Holmfeldt et al. 2013
17q21.31	*ATXN7L3** ¥	NM_001382309.1	4/13	**17q21 deletions in up to 9% of B-ALL cases, involving UBTF-ATXN7L3 fusions ¥** Kimura et al. 2022, Fioretos et al. 2022, Passet et al. 2022
	UBTF* ¥	NM_0142233.4	11/21	
17q22	*HLF** ¥	NM_002126.5	4/4	**(Rare) *TCF3-HLF* fusion ¥ described in B-ALL** Panagopoulos et al. 2012, Lejman et al. 2020
18p11.21	*PTPN2*	NM_002828.4	4/9	**Deletions of *PTPN2* in 6% of T-ALL** Kleppe et al. 2010
19p13.3	*DAZAP1** ¥	NM_018959.4	6/12	***MEF2D-DAZAP1* fusion ¥ in B-ALL** Gu et al. 2016, Yuki et al. 2004
19p13.3	*TCF3** ¥	NM_003200.5	7/19	***(Rare) TCF3-HLF* fusion ¥ in B-ALL** Panagopoulos et al. 2012, Lejman et al. 2020
19p13.2	*SWSAP1**		1/2	*Included as flanking probe for EPOR*
	EPOR*	NM_000121.4	8/8	**Rearrangements involving *EPOR* and *IGH* in B-ALL** Iacobucci et al. 2016, Roberts et al. 2012, Zur Stadt et al. 2019
	RGL3*		1/19	*Included as flanking probe for EPOR*
19q13.2	*HNRNPUL1** ¥	NM_007040.6	6/15	**Fusion partner of *MEF2D* ¥ in B-ALL** Gu et al. 2016, Ohki et al. 2019
20q11.21	*BCL2L1**	NM_138578.3	2/3	**20q11.21 (dic(9;20) breakpoint)** An et al. 2008, An et al. 2009, Antic et al. 2023
	ASXL1*		1/13	
	DNMT3B*	NM_006892.4	2/23	
	SUN5*		1/13	
21q11.2	*HSPA13*			**iAMP21, a region of amplification on chromosome 21, which contains at least *RUNX1*** Robinson et al. 2003, Moorman et al. 2007, Harrison et al. 2014, Koleilat et al. 2022
21q11.2	*SAMSN1*			
21q21.1	*MIR99A*			
21q21.1	*BTG3*			
21q21.1	*TMPRSS15*			
21q21.1	*NCAM2*	-	1 probe for each gene	
21q21.3	*MIR155*			
21q21.3	*APP*			
21q21.3	*CYYR1*			
21q21.3	*ADAMTS5*			
21q21.3	*BACH1*			
21q22.11	*TIAM1*			
21q22.11	*OLIG2*			
21q22.11	*KCNE2*			

Chromosomal position (hg38)	Gene	NM sequence (a)	# probes / # exons in gene	Remarks and literature
21q22.12	**RUNX1** ±	NM_001754.5	6/9	
21q22.13	SIM2	-	1 probe for each gene	
21q22.13	HLCS			
21q22.13	DYRK1A			
21q22.13	KCNJ6			
21q22.2	**ERG** ≠	NM_182918.4	12/10	**Short intragenic deletions of *ERG* in BCP-ALL** Clappier et al. 2014 ***IKZF1*plus profile (unfavorable prognosis): absence of *ERG* deletions** Stanulla et al. 2018
21q22.2	ETS2	-	1 probe for each gene	**iAMP21, a region of amplification on chromosome 21, which contains at least *RUNX1*** Robinson et al. 2003, Moorman et al. 2007, Harrison et al. 2014, Koleilat et al. 2022
21q22.2	PSMG1			
21q22.3	TMPRSS2			
21q22.3	RIPK4			
21q22.3	TFF1			
21q22.3	ITGB2			
21q22.3	SLC19A1			
21q22.3	COL6A2			
21q22.3	PRMT2 «			
22q11.22	TOP3B*	-	1/18	**22q11.22 microdeletion region in 40% of B-ALL** Mangum et al. 2021
	PRAMENP*	NR_135291.1	2/7	
	IGLV8-61*, IGLV4-60*	-	4 probes in or next to these genes	
	VPREB1	NM_007128.4	2/2	**Focal deletions of *VPREB1* in ~30% of B-ALL cases** Mangum et al. 2014, Chen et al. 2016
	BMS1P20*, IGLV7-43*	-	2 probes in or around these genes	
22q11.23	IGLL1	-	1/3	*Included as flanking probe for 22q11.22 microdeletion region*
Xp22.33	SHOX	NM_000451.4	5/5	**Frequent rearrangements in PAR1 region** Mullighan et al. 2009b, Russell et al. 2009 **Included in *IKZF1*plus profile – frequently co-deleted in ALL, unfavorable prognosis** Stanulla et al. 2018
Xp22.33	CRLF2 «	NM_022148.4	6/8	
Xp22.33	CSF2RA	NM_172245.4	15/13	
Xp22.33	IL3RA	NM_002183.4	8/12	
Xp22.33	P2RY8	NM_178129.5	3/2	
Xp22.33	AKAP17A	-	1 probe for each gene	
Xp22.33	ASMT «			
Xp22.33	ZBED1			
Xp22.33	CD99			
Xp22.33	Flanking probes for PAR1 region	-	1 probe for GYG2	
Yp11.2			1 probe for SRY	
Xp21.1-p21.2	DMD	NM_004006.3	7/79	**Recurrent deletion of *DMD*, present in relapse cases** Kawamata et al. 2008, Mullighan et al. 2008b
Xq26.2	PHF6 «	NM_001015877.2	4/11	**Deletions of *PHF6* in 3% of T-ALL** Van Vlierberghe et al. 2010

(a) NM sequence and MANE: **We have adopted the MANE exon numbering. Please be aware that the MANE and LRG exon numbering does not always correspond.** When MANE is not available, then the exon numbering is based on the NM or NG sequence. The exon numbering and NM_ sequence used have been retrieved on 09/2024. As changes to the MANE database can occur after release of this product description, exon numbering may not be up-to-date. Exon numbering used here may differ from literature.

More information on the location and warnings of the probes present in this probemix can be found in the Probe Information File (PIF) available on the product page at www.mrcholland.com.

* New in version B1.

« Changed in version B1.

¥ D007 Acute Lymphoblastic Leukemia can provide an *indication* for the presence of fusion genes. These should always be confirmed with other methods.

± This gene is highlighted within this region as historically three or more extra copies of *RUNX1* on a single abnormal chromosome 21 (a total of five or more *RUNX1* signals per cell) was used to define iAMP21 (Harrison et al. 2014). It is now known that changes in this region might be more complex (Koleilat et al. 2022).

≠ This gene is highlighted within this region as it is important within the iAMP21 region, but also has relevance in combination with other CNAs outside the context of the iAMP21 region.

Table 2. Karyotyping probes

Chromosomal position (hg38)	Gene	Chromosomal position (hg38)	Gene
1p36.33	TMEM240	5p15.33	IRX4
1p36.33	CFAP74	5p15.31	NSUN2 §
1p32.3	ACOT11 §	5p15.2	DNAH5
1p32.2	PLPP3 §	5p13.3	DROSHA
1p13.1	SLC22A15 §	5p13.3	NPR3 §
1p12	SPAG17 §	5q11.2	ITGA2 §
1q21.3	RPRD2 §	5q11.2	DHX29 §
1q21.3	NUP210L §	5q11.2	IL31RA §
1q31.3	KCNT2 §	5q11.2	MIER3
1q31.3	DENND1B	5q23.2	MEGF10 §
1q44	ADSS2 §	5q31.2	MYOT §
1q44	DESI2	5q35.3	COL23A1 §
2p25.3	TMEM18	5q35.3	MAPK9 §
2p25.3	COLEC11 §	6p25.2	SERPINB6
2p22.3	SPAST §	6p25.2	ECI2
2p22.2	VIT	6p22.1	ZFP57
2q11.2	FER1L5	6p21.33	ATAT1
2q11.2	CNNM3	6p12.1	RAB23
2q11.2	NPAS2 §	6p11.2	PRIM2
2q24.3	SCN1A	6q13	COL19A1
2q31.1	ABCB11 §	6q13	RIMS1
2q37.3	CAPN10	6q22.31	TBC1D32
2q37.3	KIF1A	6q22.33	LAMA2
3p26.2	TRNT1 §	6q27	SMOC2
3p26.1	SUMF1 §	6q27	ERMARD
3p24.2	NR1D2 §	7p22.2	SDK1 §
3p24.1	NEK10 §	7p22.1	RADIL
3p12.3	CNTN3 §	7p15.3	RAPGEF5 §
3p11.1	HTR1F §	7p15.3	STK31 §
3q11.2	EPHA6 §	7p12.3	ADCY1 §
3q12.1	CPOX §	7p12.3	ABCA13 §
3q23	XRN1 §	7p11.2	LANCL2 *
3q24	SLC9A9 §	7p11.2	SUMF2
3q29	OPA1 §	7q11.21	KCTD7 §
3q29	ACAP2	7q11.22	GALNT17 §
4p16.3	LETM1	7q31.1	PNPLA8 §
4p16.3	ADD1	7q31.1	IFRD1 §
4p15.31	KCNIP4	7q36.3	RBM33 §
4p15.2	DHX15	7q36.3	DYNC2I1
4p12	COMMD8	8p23.3	FBXO25
4p12	NFXL1	8p23.3	CLN8
4q13.1	TECRL	8p21.3	GFRA2
4q13.2	UGT2A1	8p21.2	CDCA2
4q31.21	INPP4B	8p12	RBPMS
4q31.22	ZNF827	8p12	GSR
4q35.2	CYP4V2		
4q35.2	TRIML1		

Chromosomal position (hg38)	Gene	Chromosomal position (hg38)	Gene
8q11.21	SNTG1	12q12	KIF21A §
8q12.2	CHD7 *	12q12	NELL2 §
8q21.3	RMDN1	12q23.1	NEDD1 §
8q21.3	CPNE3	12q23.1	SLC17A8 §
8q24.3	TSNARE1	12q24.33	GALNT9
8q24.3	SLC39A4	12q24.33	PGAM5
9p24.3	DOCK8	13q12.3	KATNAL1 §
9p24.3	KANK1	13q14.3	VPS36 §
9p24.1	GLDC	13q21.33	KLHL1
9p22.3	FREM1	13q34	ARHGEF7 §
9p22.2	BNC2 §	13q34	GRK1 §
9p13.2	FBXO10 §	14q11.2	TEP1
9p13.2	DCAF10 §	14q11.2	CHD8
9q21.11	PGM5	14q22.1	DDHD1
9q21.12	TRPM3 §	14q22.2	SAMD4A
9q22.33	ANKS6 §	14q32.31	DYNC1H1
9q31.1	ALDOB §	14q32.33	COA8
9q34.3	GRIN1	15q12	ATP10A §
9q34.3	EHMT1 §	15q13.1	OCA2 §
10p15.3	DIP2C	15q22.2	VPS13C §
10p15.2	PFKP	15q22.31	USP3 *
10p13	NMT2	15q26.1	BLM *
10p13	ITGA8	15q26.3	CHSY1 §
10p11.21	CUL2	15q26.3	TM2D3
10p11.21	ZNF25	16p13.3	DECR2
10q11.21	MARCHF8	16p13.3	IFT140 §
10q11.22	ARHGAP22	16p13.13	TXNDC11 §
10q22.2	KAT6B	16p13.12	CPPED1 §
10q22.3	LRMDA	16p11.2	HIRIP3
10q26.3	INPP5A	16p11.2	ITGAL §
10q26.3	KNDC1	16q11.2	GPT2 §
11p15.5	RIC8A	16q12.1	LONP2 §
11p15.5	DEAF1	16q22.1	SLC12A4
11p14.3	ANO5 §	16q22.1	DUS2 §
11p14.2	SLC5A12 §	16q24.3	ANKRD11 §
11p11.2	LRP4 §	16q24.3	GAS8
11p11.2	NUP160 §	17p13.3	VPS53
11q12.1	SERPING1 §	17p13.3	NXN
11q12.3	BEST1 §	17p13.1	PIK3R6
11q14.3	FAT3 §	17p13.1	USP43
11q21	MTMR2 §	17p11.2	RAI1
11q25	NTM	17p11.2	ULK2
11q25	NCAPD3 §	17q11.2	MYO18A
12p13.33	WNK1 §	17q11.2	PSMD11
12p13.33	CACNA2D4	17q22	ANKFN1
12p12.3	PTPRO §	17q23.2	MED13
12p12.3	AEBP2 §	17q25.3	CCDC57
12p11.22	FAR2 §	17q25.3	CSNK1D
12p11.22	TMTC1 §		

Chromosomal position (hg38)	Gene	Chromosomal position (hg38)	Gene
18p11.32	*CLUL1*	20q11.22	*ACSS2* §
18p11.31	*LPIN2*	20q11.22	*EDEM2* §
18p11.31	*MYOM1*	20q13.12	*SLC13A3* §
18p11.21	*GNAL*	20q13.13	*STAU1*
18p11.21	*SPIRE1*	20q13.33	*OSBPL2*
18p11.21	*LDLRAD4*	20q13.33	*UCKL1* *
18p11.21	*FAM210A*	21q11.2	*RBM11*
18q11.2	*RBBP8*	21q22.11	*ITSN1*
18q11.2	*NPC1*	21q22.3	*PDE9A*
18q21.1	*LOXHD1*	21q22.3	*TRAPPC10*
18q21.1	*LIPG*	21q22.3	*TSPEAR*
18q23	*CTDP1*	22q11.1	*GAB4* §
18q23	*TXNL4A*	22q11.21	*CECR2* §
19p13.3	*PLPP2*	22q12.2	*ZMAT5* §
19p13.3	*CDC34*	22q12.2	*SFI1* §
19p13.2	*GCDH*	22q13.31	*TRMU* §
19p13.2	*STX10*	22q13.33	*BRD1* *
19p13.11	*JAK3*	Xp22.31	*ANOS1*
19p13.11	*GMIP*	Xp22.11	*ACOT9*
19q12	*POP4*	Xp11.22	*FGD1*
19q13.11	*SLC7A9*	Xq11.1	*ARHGEF9*
19q13.31	*KCNN4*	Xq13.3	*ZDHHC15*
19q13.32	*FKRP*	Xq22.1	*NXF3*
19q13.42	*DNAAF3* §	Xq28	*CLIC2*
19q13.43	*SLC27A5*	Xq28	*TMLHE*
20p13	*RSPO4*	Yp11.2	*PCDH11Y*
20p13	*TGM6* §	Yp11.2	*TBL1Y*
20p12.3	*TRMT6* §	Yq11.221	*USP9Y*
20p12.2	*PLCB4*	Yq11.223	*KDM5D*
20p11.23	*RIN2*	Yq11.223	*RPS4Y2*
20p11.21	*APMAP* §		

§ Used as reference probe for normalisation purposes in data analysis using the Coffalyser digitalMLPA *D007-B1 default* product sheet. A different selection of reference probes is present in the *D007-B1 near haploid_low hypodiploid* product sheet (see Table 3).
* New in version B1.
Note: No karyotyping probes are present in the acrocentric chromosome p arms.

More information on the location and warnings of the probes present in this probemix can be found in the Probe Information File (PIF) available at www.mrcholland.com.

Table 3. Reference probe selection for low near haploidy and low hypodiploidy

Chromosome	Number of reference probes	Gene names
Retained in near haploidy and low hypodiploidy		
Chromosome 8	6	*CLN8, RBPMS, GSR, SNTG1, RMDN1, CPNE3*
Chromosome 10	9	*DIP2C, NMT2, CUL2, ZNF25, MARCHF8, ARHGAP22, KAT6B, LRMDA, INPP5A*
Chromosome 14	6	*TEP1, CHD8, DDHD1, SAMD4A, DYNC1H1, COA8*
Chromosome 18	10	*LPIN2, GNAL, SPIRE1, LDLRAD4, FAM210A, RBBP8, NPC1, LOXHD1, LIPG, CTDP1*
Chromosome 21	4	*RBM11, ITSN1, PDE9A, TRAPPC10*
Chromosome X and Y	30	*PAR1 region including SHOX, CRLF2, CSF2RA, IL3RA, P2RY8, AKAP17A, ZBED1, CD99*
Additionally retained in hypodiploidy		
Chromosome 1	4	*PLPP3, SLC22A15, NUP210L, ADSS2*
Chromosome 5	4	*NSUN2, NPR3, IL31RA, COL23A1*
Chromosome 6	4	*ECI2, PRIM2, LAMA2, ERMARD*
Chromosome 11	4	*ANO5, BEST1, MTMR2, NCAPD3*
Chromosome 22	3	*GAB4, ZMAT5, SFI1*

Table 4. Related SALSA® MLPA® probemixes

Related probemix	Gene(s)	Coverage ±	Can be used for confirmation ^
P047 RB1	*RB1*	Contains probes for each exon of *RB1*, except for exon 15.	Yes
P056 TP53	*TP53*	Contains probes for each exon of *TP53*.	No
P081/P082 NF1	*NF1*	Contain probes for each exon of *NF1*.	Yes
P105 Glioma	*CDKN2A, PTEN, TP53*	Contains one probe for each exon of *CDKN2A* and *PTEN*. Also contains 9 probes for *TP53*.	No
P175 Tumour Gain	*ABL1*	Contains probes for exons 1 and 12 of *ABL1*.	Yes
P202 IKZF1-ERG	*IKZF, ERG*	Contains probes for each exon of *IKZF1* and *ERG*.	Yes
P225 PTEN	*PTEN*	Contains at least two probes for each exon of *PTEN*.	No
P298 BRAF-HRAS-KRAS-NRAS	*BRAF, HRAS, KRAS, NRAS*	Contains 9 probes targeting *KRAS*.	Yes
P323 CDK4-HMGA-MDM2	*CDK4, HMGA, MDM2*	Contains probes on chromosomal arms 12p and 12q.	Yes
P327 iAMP21-ERG	*iAMP21, ERG*	Contains probes for the iAMP21 region, including probes for *RUNX1* and for each exon of *ERG*.	Yes
P329 CRLF2-CSF2RA-IL3RA	*CRLF2, CSF2RA, IL3RA*	Contains probes for *SHOX, CRLF2, CSF2RA, IL3RA* and *P2RY8*.	Yes
P335 ALL-IKZF1	*IKZF1*	Contains probes for *EBF1, IKZF1, PAX5, ETV6, BTG1, RB1* and the PAR1 region.	Yes
P370 BRAF-IDH1-IDH2	*MYB*	Contains several probes for *MYB*.	Yes
P377 Hematologic Malignancies	*IKZF1, RUNX1, RB1*	Contains several probes for *IKZF1, RUNX1, RB1* and flanking probes *DLEU1* and *DLEU2*.	Yes
P383 T-ALL	Multiple	Contains probes for *TAL1, STIL, LEF1, CASP8AP2, MYB,*	Yes

Related probemix	Gene(s)	Coverage ±	Can be used for confirmation ^
		EZH2, *MLLT3*, *ABL1*, *NUP214*, *LMO1/2*, *RAG2/CD44/SLC1A2*, *NF1*, *SUZ12*, *PTPN2* and *PHF6*.	
P414 MDS	*EGR1, SPARC*	Contains seven probes for 5q31.2-q33.3 (including additional probes for *EGR1* and *SPARC*).	Yes
P419 CDKN2A/2B-CDK4	*CDKN2A, CDKN2B*	Contains multiple probes for each exon of *CDKN2A* and *CDKN2B*.	Yes
P437 Familial MDS-AML	*RUNX1*	Contains one probe for each exon of *RUNX1*.	Yes
ME024 9p21 CDKN2A/2B region	*CDKN2A, CDKN2B, MTAP*	Contains probes for each exon of *CDKN2A*, *CDKN2B* and *MTAP*.	Yes

± Only genes or chromosomal regions included in D007 Acute Lymphoblastic Leukemia are mentioned in this table. SALSA®
MLPA® probemixes additionally contain probes for genes not mentioned in this table.

^ Probemixes can be used for confirmation when most ligation sites are different between D007-B1 Acute Lymphoblastic
Leukemia probes and the probes in the corresponding probemixes. Of note, this statement concerns the majority of the probes in
a probemix and does not mean that all probes always have a different ligation site. For more information, please contact
info@mrcholland.com.

References

- Agirre X et al. (2003). TP53 is frequently altered by methylation, mutation and/or deletion in acute lymphoblastic leukaemia. *Mol Carcinog*. 38:201-8.
- Al Zaabi EA et al. (2010). Multiplex ligation-dependent probe amplification versus multiprobe fluorescence in situ hybridization to detect genomic aberrations in chronic lymphocytic leukemia: A tertiary center experience. *J Mol Diagn*. 12:197-203.
- An Q et al. (2008). Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. *PNAS*. 105:17050-4.
- An Q et al. (2009). Heterogeneous breakpoints in patients with acute lymphoblastic leukemia and the dic(9;20)(p11~13;q11) show recurrent involvement of genes at 20q11.21. *Haematologica*. 94:1164-9.
- Antić Ž et al. (2023). Recurrent DNMT3B rearrangements are associated with unfavorable outcome in dicentric (9;20)-positive pediatric BCP-ALL. *Leukemia*. 37:2522-5.
- Balgobind BV et al. (2008). Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. *Blood*. 111:4322-8.
- Barbosa TC et al. (2018). A novel PAX5 rearrangement in TCF3-PBX1 acute lymphoblastic leukemia: a case report. *BMC Med Genomics*. 11:122.
- Benard-Slagter A et al. (2017). Digital multiplex ligation-dependent probe amplification for detection of key copy number alterations in T- and B-cell lymphoblastic leukemia. *J Mol Diagn*. 19: 659-72.
- Bertin R et al. (2003). CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. *Genes Chrom Cancer*. 37:44-57.
- Bhandari P et al. (2017). Molecular profiling of gene copy number abnormalities in key regulatory genes in high-risk B-lineage acute lymphoblastic leukemia: frequency and their association with clinicopathological findings in Indian patients. *Med Oncol*. 34:92.
- Boer JM et al. (2016). Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. *Leukemia*. 30:32-8.
- Bond J et al. (2019). *DNMT3A* mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. *Haematologica.* 104:1617-25.
- Carroll AJ et al. (2019). Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. *Cancer Genet*. 238:62-8.
- Cavé H et al. (2004). Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. *Blood*. 103:442-50.

- Chang TC et al. (2024). Genomic determinants of outcome in acute lymphoblastic leukemia. *J Clin Oncol*. Epub, online ahead of print.
- Charmsaz S et al. (2013). Expression and function of the Eph receptor family in leukemia and hematopoietic malignancies: Prospects for targeted therapies. *J Leukemia*. 1:1-9.
- Chen A et al. (2016). The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and Clinical Outcome in Acute Lymphoblastic Leukemia. *PLoS One*. 11:e0162638.
- Clappier E et al. (2007). The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. *Blood*. 110:1251-61.
- Clappier E et al. (2014). An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. *Leukemia*. 28:70-7.
- Colomer-Lahiguera S et al. (2017). MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy. *Leuk Lymphoma*. 58:2895-904.
- Coll-Mulet L et al. (2008). Multiplex ligation-dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukaemia. *Br J Haematol*. 142:793-801.
- Cordas Dos Santos DM et al (2018). MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB. *BMC Cancer*. 18:663.
- Craux C et al. (2009). Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. *Leukemia*. 23:125-33.
- Fedullo AL et al. (2019). Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. *Haematologica*. 104:312-8.
- Fioretos T. Why B(-)other? About the gap of unknowns in ALL. *Blood*. 139:3455-7.
- Ghazavi F et al. (2015). CD200/BTLA deletions in pediatric precursor B-cell acute leukemia treated according to the EORTC-CLG 58951 protocol. *Haematologica*. 100:1311-9.
- Gu Z et al. (2016). Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. *Nat Commun*. 7:13331.
- Gutierrez A et al. (2010). Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. *Blood*. 115:2845-51.
- Harrison CJ et al. (2004). Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. *Br J Haematol*. 125:552-9.
- Harrison CJ et al (2014). An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. *Leukemia*. 28:1015–21.
- Haydu JE et al. (2012). An activating intragenic deletion in NOTCH1 in human T-ALL. *Blood*. 119:5211-4.
- Holmfeldt L. et al. (2013). The genomic landscape of hypodiploid acute lymphoblastic leukemia. *Nat Genet*. 45:242-52.
- Hömig-Hölzel C and Savola S (2012). Multiplex ligation-dependent probe amplification (MLPA) in tumor diagnostics and prognostics. *Diagn Mol Pathol*. 21:189-206.
- Homminga I et al. (2011). Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. *Cancer Cell*. 19:484-97.
- Iacobucci I et al. (2016). Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. *Cancer Cell*. 29:186-200.
- Jones CL et al. (2014). Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. *J Biol Chem*. 289:20502-15.
- Kawamata N et al. (2008). Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. *Blood*. 111:776-84.
- Kimura S et a. (2022). Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. *Blood*. 139:3519-31.
- Kleppe M et al. (2010). Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. *Nat Gen*. 42:530-35.

- Ko DH et al. (2011). Native ETV6 deletions accompanied by ETV6-RUNX1 rearrangements are associated with a favourable prognosis in childhood acute lymphoblastic leukaemia: a candidate for prognostic marker. *Br J Haematol*. 155:530-3.
- Koleilat A et al. (2022). Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group. *Genes Chromosomes Cancer*. 61:710-9.
- Kuster L et al. (2011). ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling. *Blood*. 117:2658-67.
- La Starza R et al. (2016). Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. *Haematologica*. 101:951-8.
- Lejman M et al. (2020). Comprehensive chromosomal aberrations in a case of a patient with TCF3-HLF-positive BCP-ALL. *BMC Med Genomics*. 13:58.
- Lengline E et al. (2013). Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. *Haematologica*. 98:e146-8.
- Lopes BA et al. (2023). The recombinome of IKZF1 deletions in B-cell precursor ALL. *Leukemia*. 37:1727-1.
- Mangum DS et al. (2014). VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia. *Leukemia*. 28:216-20.
- Mangum DS et al. (2021). Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. *JAMA Oncol*. 7:1521-8.
- Mendes RD et al. (2014). PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events. *Blood*. 124:567-78.
- Mirebeau D et al. (2006). The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. *Haematologica*. 91:881-5.
- Moorman AV et al. (2007). Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. *Lancet Oncol*. 11:429-38.
- Mullighan CG et al. (2007). Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature*. 446:758-64.
- Mullighan CG et al. (2008a). BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. *Nature*. 453:110-4.
- Mullighan CG et al. (2008b). Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. *Sci*. 322:1377-80.
- Mullighan CG et al. (2009a). Global genomic characterization of acute lymphoblastic leukemia. *Semin Hematol*. 46:3-15.
- Mullighan CG et al. (2009b). Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukaemia. *Nat Genet*. 41:1243-6.
- Mullighan CG et al. (2011). CREBBP mutations in relapsed acute lymphoblastic leukaemia. *Nature*. 471:235-9.
- Nachman JB et al. (2007). Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. *Blood*. 110:1112-5.
- Ntziachristos P et al. (2012). Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. *Nat Med*. 18: 298-301.
- O'Neil J et al. (2007). Alu elements mediate MYB gene tandem duplication in human T-ALL. *J Exp Med*. 204:3059-66.
- Ohki K et al. (2019). Tokyo Children's Cancer Study Group (TCCSG). Clinical and molecular characteristics of *MEF2D* fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in *MEF2D-HNRNPH1* gene fusion. *Haematologica*. 104:128-37.
- Okamoto R et al. (2010). Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia. *Haematologica*. 95:1481-8.

- Olsson L et al. (2014). Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. *Leukemia*. 28:302-10.
- Oram SH et al. (2013). Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia. *Leukemia*. 27:1348-57.
- Panagopoulos I et al. (2012). A novel TCF3-HLF fusion transcript in acute lymphoblastic leukemia with a t(17;19)(q22;p13). *Cancer Genet*. 205:669-72.
- Parker H et al. (2008). The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1. *Genes Chromosomes Cancer*. 47:1118-25.
- Passet M et al. (2022). Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL. *Blood*. 139:3505-18.
- Patra N et al. (2021). Clinico-hematological profile and copy number abnormalities in a cohort of STIL-TAL1 and NUP214-ABL1 positive pediatric T-cell acute lymphoblastic leukemia. *Indian J Hematol Blood Transfus*. 37:555-62.
- Paulsson K et al. (2007). Characterisation of genomic translocation breakpoints and identification of an alternative TCF3/PBX1 fusion transcript in t(1;19)(q23;p13)-positive acute lymphoblastic leukaemias. *Br J Haematol*. 138:196-201.
- Remke M et al. (2009). High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. *Blood*. 114:1053-62.
- Roberts KG et al (2012). Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. *Cancer Cell*. 22:153-66.
- Roberts KG and Mullighan CG (2015). Genomics in acute lymphoblastic leukaemia: insights and treatment implications. *Nat Rev Clin Oncol*. 12:344-57.
- Robinson HM et al. (2003). Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. *Leukemia*. 17:2249-50.
- Rowsey RA et al. (2019). Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion. *Blood Cancer J*. 9:81.
- Russell LJ et al. (2009). Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukaemia. *Blood*. 114:2688-98.
- Safavi S et al. (2014). Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia. *Haematologica*. 100:55-61.
- Safavi S and Paulsson K. (2017). Near-haploid and low-hypodiploid acute lymphoblastic leukemia: two distinct subtypes with consistently poor prognosis. *Blood*. 129:420-3.
- Salmoiraghi S et al. (2013). Mutations and chromosomal rearrangements of JAK2: Not only a myeloid issue. *Expert Rev Hematol*. 6:429-39.
- Schouten JP et al. (2002). Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. *Nucleic Acids Res*. 30:e57.
- Schwab CJ et al. (2013). Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. *Haematologica*. 98:1081-8.
- Schwab CJ et al. (2017). Intragenic amplification of PAX5: A novel subgroup in B-cell precursor acute lymphoblastic leukemia? *Blood Adv*. 1:1473-7.
- Schwartz M et al. (2007). Deletion of exon 16 of the dystrophin gene is not associated with disease. *Hum Mutat*. 28:205.
- Stanulla M et al. (2018). IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. *J Clin Oncol*. 36:1240-9.
- Stanulla M et al. (2020). IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? *Blood*. 135:252-60.

- Sulong S et al. (2009). A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. *Blood*. 113:100-7.
- Suzuki K et al. (2016). MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents. *J Clin Oncol*. 34:3451-9.
- Trageser D et al. (2009). Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. *J Exp Med*. 206:1739-53.
- Van Vlierberghe P et al. (2006). The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. *Blood*. 108:3520-9.
- Van Vlierberghe P et al. (2010). PHF6 mutations in T-cell acute lymphoblastic leukemia. *Nat Gen*. 42:338-42.
- Varga RE et al. (2012). MLPA-based evidence for sequence gain: pitfalls in confirmation and necessity for exclusion of false positives. *Anal Biochem*. 421:799-801.
- Vicente C et al. (2015). Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. *Haematologica*. 100:1301-10.
- Waanders E et al. (2012). The origin and nature of of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution. *PLoS Genet*. 8:e1002533.
- Weston BW et al. (2013). Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. *J Clin Oncol*. 31:e413-6.
- Yang JJ et al. (2008). Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. *Blood*. 112:4178−83.
- Yang M et al. (2020). 13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking. *Blood*. 136:946-56.
- Yu X et al. (2015). TOX gene: a novel target for human cancer gene therapy. *Am J Cancer Res*. 5:3516-24.
- Yuki Y et al. (2004). Identification of a novel fusion gene in a pre-B acute lymphoblastic leukemia with t(1;19)(q23;p13). *Cancer Sci*. 95:503-7.
- Zhang J et al. (2012). The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature*. 481:157-63.
- Zuurbier L et al. (2012). The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. *Haematologica*. 97:1405-13.

Selected publications using D007 Acute Lymphoblastic Leukemia

- Antić Z et al. (2022). Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse. *Pediatr Blood Cancer*. 69:e29361.
- Bedics G et al. (2023). PersonALL: a genetic scoring guide for personalized risk assessment in pediatric B-cell precursor acute lymphoblastic leukemia. *Br J Cancer*. 129:455-65.
- Benard-Slagter A et al. (2017). Digital multiplex ligation-dependent probe amplification for detection of key copy number alterations in T- and B-cell lymphoblastic leukemia. *J Mol Diagn*. 19:659-72.
- Blunck CB et al. (2024). Characterisation of cells markers associated with IKZF1plus in BCP-ALL. *Transl Oncol*. 50:102127.
- Kiss R et al. (2020). Comprehensive profiling of disease-relevant copy number aberrations for advanced clinical diagnostics of pediatric acute lymphoblastic leukemia. *Mod Pathol*. 33:812-24.
- Lopes BA et al. (2023). The recombinome of IKZF1 deletions in B-cell precursor ALL. *Leukemia*. 37:1727-31.
- Maciel ALT et al. (2022). IKZF1 deletions associate with CRLF2 overexpression leading to a poor prognosis in B-cell precursor acute lymphoblastic leukaemia. *Transl Oncol*. 15:101291.
- Palmi C et al. (2023). Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia. *Hemasphere*. 7:e892.
- Péterffy B et al. (2025). Molecular Profiling Reveals Novel Gene Fusions and Genetic Markers for Refined Patient Stratification in Pediatric Acute Lymphoblastic Leukemia. *Mod Pathol*. 38:100741.
- Thakral D et al. (2019). Rapid identification of key copy number alterations in B- and T-cell acute lymphoblastic leukemia by digital multiplex ligation-dependent probe amplification. *Front Oncol*. 9:871.
- Zur Stadt U et al. (2019). Characterization of novel, recurrent genomic rearrangements as sensitive MRD targets in childhood B-cell precursor ALL. *Blood Cancer J*. 9:96.

D007 Acute Lymphoblastic Leukemia product history	
Version	*Modification*
A1	First release.
B1	One target probe removed, 16 probes replaced, and 194 new probes have been added targeting regions and genes of (emerging) interest.

Implemented changes in the product description

Version B1-05 − 10 December 2025 (05)
- Modifications throughout the document to make this product description compatible with software version Coffalyser digitalMLPA 2.5.0 or higher, especially with regards to reference sample selection.
- P474 probemix was removed from Table 4.
- Positive control DNA samples section: information moved to product page on website.
 	
Version B1-04 − 23 September 2025 (05)
- Modification of cut-off values for inter ratios of X- and Y-chromosome-specific probes in male samples in the table in "Interpretation of results" on page 6.
- Adjustments in Table 1. Positive samples from biobanks tested by MRC Holland, on page 4.
- Various minor textual changes.
- New reference added to *Selected publications using D007* on page 22.
 	
Version B1-03 − 24 July 2025 (05)
- Products' names were updated throughout the document from SALSA® digitalMLPA™ to NXtec.
- Modifications in the 'Required specimens' section regarding DNA extraction and tumour cell percentage.
- 'Performance characteristics' section was removed.
- 'Interpretation of results' section in the table the borders for normal samples were updated: < was replaced for ≤.
- Product description adapted to a new template.
 	
Version B1-02 − 24 January 2025 (04)
- Added inter ratio values for interpretation of X- and Y-chromosome-specific probe results in 'Interpretation of results' section on page 6.
 	
Version B1-01 − 08 November 2024 (04)
- Product description adapted to a new product version.
- Tables in this product description updated with newest information.
- New cut off values for deletions and gains introduced on page 6. Please note that these borders are different than those in the D007-A1 product description.
- New positive samples added to Table 1.
- New references added on pages 18-23.
- Various minor textual changes.
 	
Version A1-02 − 08 January 2024 (03)
    - Replaced "SALSA digitalMLPA" with "SALSA® digitalMLPA™" where applicable.
    - To be used with: section restructured and reagent kits (Cat No: DRK05-IL, DRK20-IL) added.
    - Barcode plate names and lot numbers updated.
    - Added sections: Ingredients, SDS note, Storage and handling, information on shelf life and safe disposal.
    - Updated links to our website to https://www.mrcholland.com throughout the document.
    - Various minor textual changes.
 	
Version A1-01 − 3 November 2022 (03)
    - Not applicable, new document.

More information: www.mrcholland.com; www.mrcholland.eu	
🏭	MRC Holland BV; Willem Schoutenstraat 1 1057 DL, Amsterdam, The Netherlands
E-mail	info@mrcholland.com (information & technical questions) order@mrcholland.com (orders)
Phone	+31 888 657 200